(211)At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

Levillain H, Moës AR, Gameiro-Paris C, Abrunhosa A, Deakin T, Gebhart G, Herth MM, Gestin JF, Haddad F, Jensen AI, Bue RL, Mikolajczak R, Otamendi A, Staunton-Mann K, Tabury K, Flamen P, Accelerate.EU consortium

Open source

DOI: 10.1007/s00259-026-07950-y
Published: 2026 Aug
Container: European journal of nuclear medicine and molecular imaging
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00259-026-07950-y,
  title = {(211)At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.},
  author = {Levillain H and Moës AR and Gameiro-Paris C and Abrunhosa A and Deakin T and Gebhart G and Herth MM and Gestin JF and Haddad F and Jensen AI and Bue RL and Mikolajczak R and Otamendi A and Staunton-Mann K and Tabury K and Flamen P and Accelerate.EU consortium},
  year = {2026},
  journal = {European journal of nuclear medicine and molecular imaging},
  doi = {10.1007/s00259-026-07950-y},
  url = {https://doi.org/10.1007/s00259-026-07950-y}
}

RIS

TY  - JOUR
TI  - (211)At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.
AU  - Levillain H
AU  - Moës AR
AU  - Gameiro-Paris C
AU  - Abrunhosa A
AU  - Deakin T
AU  - Gebhart G
AU  - Herth MM
AU  - Gestin JF
AU  - Haddad F
AU  - Jensen AI
AU  - Bue RL
AU  - Mikolajczak R
AU  - Otamendi A
AU  - Staunton-Mann K
AU  - Tabury K
AU  - Flamen P
AU  - Accelerate.EU consortium
PY  - 2026
JO  - European journal of nuclear medicine and molecular imaging
DO  - 10.1007/s00259-026-07950-y
UR  - https://doi.org/10.1007/s00259-026-07950-y
ER  -

APA

H, L., AR, M., C, G., A, A., T, D., G, G., MM, H., JF, G., F, H., AI, J., RL, B., R, M., A, O., K, S., K, T., P, F., & consortium, A. (2026). (211)At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-026-07950-y

Source records

pubmed · retrieved 2026-09-25T11:30:39.400Z